Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US
A study has found a higher risk of suicidal thoughts in users of Novo Nordisk's GLP-1 agonist-based drugs for diabetes and obesity, even though regulators in the US and EU concluded there w
Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefi
Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate.
Shares in Novo Nordisk and Eli Lilly have been under pressure after a study emerged suggesting that people taking a GLP-1 agonist had an elevated risk of a rare but serious eye condition.